1.36 USD
▲+0.09+8.80%
盘后 1.26 +0.65%
2026-08-03
市值
$23.77M
市盈率
—
EPS
-3.32
股息率
—
52 周区间
0.89 – 13.48
成交量
269.89K
Beta
0.56
目标价
—
52W 低 0.8952W 高 13.48
价格走势
公司简介
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,...